BridgeBio
We're hiring — explore open roles below and apply in a few clicks.
Location
Headquarters: Palo Alto, California, United States, North America
Region: California
Country: US
Continent: North America
About
BridgeBio is a biopharmaceutical company focused on designing transformative medicines for patients with genetic diseases and cancers driven by clear genetic drivers. It develops and advances therapies across its pipeline, including products like Attruby (acoramidis) and Nulibry (fosdenopterin), aiming to bring clinically meaningful cures to patients. The company emphasizes a platform that accelerates discovery and development, combining science and finance to support patients and partners. Headquartered in Palo Alto, California, BridgeBio engages in research, collaborations, and patient-focused initiatives to address rare genetic diseases and oncology indications.
BridgeBio is a biopharmaceutical company developing transformative medicines for patients with genetic diseases and cancers driven by clear genetic drivers. It advances therapies across its pipeline, including products like Acoramidis and Fosdenopterin, aiming to bring clinically meaningful cures to patients. The company emphasizes a platform that accelerates discovery and development, combining s
BridgeBio Inc.
2014
for_profit
active
Industries
Primary Industry: Business Services
Categories
Funding & Financials
Public Company
3800000000
50m-100m
ipo
NASDAQ:BBIO
nasdaq
Investors
Founders
Charles Homcy
Frank McCormick
Neil Kumar
Leadership
Justin To — Chief Operating Officer, Skeletal Dysplasias and Gene Therapy
Uma Sinha — Chief Scientific Officer
Thomas Trimarchi — President and Chief Operating Officer
Charles Homcy — Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director
Ali Panjwani — Director, Pricing & Contracting, Market Access
Technology Stack
Products
Attruby™ (acoramidis): An oral small molecule drug approved to treat transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM) by reducing cardiovascular death and hospitalization.
Acoramidis: A small molecule in Phase 3 trials aimed at preventing early-stage variant transthyretin amyloidosis (ATTRv) in asymptomatic carriers of pathogenic TTR variants.
Infigratinib (Low-dose): An oral small molecule in Phase 3 development for treating achondroplasia by inhibiting FGFR3 to improve bone growth in children.
Infigratinib (Hypochondroplasia): An oral small molecule in Phase 2 development targeting FGFR3 to treat hypochondroplasia, a rare skeletal dysplasia causing short stature.
BBP-418: An investigational oral small molecule in Phase 3 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) designed to enhance FKRP enzyme activity and improve muscle function.
Encaleret: An investigational oral small molecule negative allosteric modulator of the calcium-sensing receptor (CaSR) in Phase 3 for autosomal dominant hypocalcemia type 1 (ADH1).
Funding rounds
Post Ipo Debt · $550M · (2026-01-16)
Post Ipo Debt · $500M · (2025-02-25)
Post Ipo Equity · $250M · (2024-03-04)
